{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:28:42Z","timestamp":1789450122981,"version":"build-2803163510"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"suppl_5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11,15]]},"DOI":"10.1093\/cid\/civ551","type":"journal-article","created":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T00:33:10Z","timestamp":1447115590000},"page":"S434-S441","source":"Crossref","is-referenced-by-count":45,"title":["Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010\u20132014"],"prefix":"10.1093","volume":"61","author":[{"given":"Mamoudou H.","family":"Djingarey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien V. K.","family":"Diomand\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigue","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Kandolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Shirehwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Lingani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan T.","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Tevi-Benissan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Perea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Preziosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Marc","family":"LaForce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,11,9]]},"reference":[{"issue":"suppl 1","key":"key\n\t\t\t\t20171014025640_CIV551C1","first-page":"A97","article-title":"The Meningitis Vaccine Project","volume":"25","year":"2007","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014025640_CIV551C2","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1003812","article-title":"Immunogenicity and safety of a meningococcal A conjugate vaccine in Africa","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014025640_CIV551C3","first-page":"354","article-title":"Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd protection","volume":"56","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014025640_CIV551C4","first-page":"40","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial","volume":"383","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014025640_CIV551C5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1473-3099(12)70168-8","article-title":"Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data","volume":"12","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20171014025640_CIV551C6","first-page":"S442","article-title":"Risk assessment and meningococcal A conjugate vaccine introduction in Africa: the district prioritization tool","volume-title":"Clin Infect Dis","year":"2015"},{"key":"key\n\t\t\t\t20171014025640_CIV551C7","volume-title":"Immunization coverage cluster survey\u2014reference manual","author":"World Health Organization.","year":"2005"},{"key":"key\n\t\t\t\t20171014025640_CIV551C8","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/ije\/19.4.1086","article-title":"An evaluation of lot quality assurance sampling to monitor and improve immunization coverage","volume":"19","year":"1990","journal-title":"Int J Epidemiol"},{"key":"key\n\t\t\t\t20171014025640_CIV551C9","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.vaccine.2015.01.043","article-title":"Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso\u2014implication for introduction of PsA-TT into Expanded Programme on Immunization","volume":"33","year":"2015","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014025640_CIV551C10","doi-asserted-by":"crossref","first-page":"e29116","DOI":"10.1371\/journal.pone.0029116","article-title":"Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20171014025640_CIV551C11","first-page":"S459","article-title":"Lessons learned from enhancing vaccine pharmacovigilance activities during PsA-TT introduction in African countries, 2010\u20132013","volume-title":"Clin Infect Dis","year":"2015"},{"key":"key\n\t\t\t\t20171014025640_CIV551C12","first-page":"764","article-title":"Mass psychogenic illness following tetanus-diphtheria toxoid vaccination in Jordan","volume":"79","year":"2001","journal-title":"Bull World Health Organ"},{"key":"key\n\t\t\t\t20171014025640_CIV551C13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/00332747.1980.11024052","article-title":"The sociocultural dynamic of mass hysteria: a case study of social conflict in West Malaysia","volume":"43","year":"1980","journal-title":"Psychiatric"},{"key":"key\n\t\t\t\t20171014025640_CIV551C14","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/S0264-410X(96)00069-2","article-title":"An outbreak of vaccination panic","volume":"14","year":"1996","journal-title":"Vaccine"},{"issue":"suppl 5","key":"key\n\t\t\t\t20171014025640_CIV551C15","first-page":"S451","article-title":"Communication challenges during the development and introduction of a new meningococcal vaccine in Africa","volume":"61","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014025640_CIV551C16","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.vaccine.2014.01.038","article-title":"Benefits of using vaccines out of the cold chain: delivering meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin","volume":"32","year":"2014","journal-title":"Vaccine"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/61\/suppl_5\/S434\/20914207\/civ551.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T06:56:50Z","timestamp":1507964210000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/61\/suppl_5\/S434\/418141\/Introduction-and-Rollout-of-a-New-Group-A"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,9]]},"references-count":16,"journal-issue":{"issue":"suppl_5","published-online":{"date-parts":[[2015,11,9]]},"published-print":{"date-parts":[[2015,11,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/civ551","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,11,15]]},"published":{"date-parts":[[2015,11,9]]}}}